Statistics for A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Total visits
views | |
---|---|
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study | 264 |
Total visits per month
views | |
---|---|
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 0 |
April 2025 | 0 |
May 2025 | 0 |
File Visits
views | |
---|---|
nihms734272.pdf | 409 |
java.util.UUID:b2c46861-e2a7-4a29-b75c-06e9f3b0feeb | 78 |
java.util.UUID:c62e2869-34b1-48d0-9588-b763f177a3b3 | 10 |
java.util.UUID:a7ad6a35-c467-4822-872b-a5dfe26c9f82 | 4 |
Top country views
views | |
---|---|
United States | 192 |
Germany | 17 |
Sweden | 9 |
Ukraine | 8 |
Russia | 6 |
China | 4 |
United Kingdom | 3 |
Canada | 2 |
Poland | 2 |
France | 1 |
India | 1 |
Italy | 1 |
Malaysia | 1 |
Philippines | 1 |
Top city views
views | |
---|---|
Wilmington | 48 |
Fairfield | 32 |
Ann Arbor | 24 |
Kiez | 15 |
Houston | 12 |
Cambridge | 9 |
White Plains | 9 |
Stockholm | 8 |
Jacksonville | 7 |
Kiev | 7 |
Beijing | 3 |
Saint Petersburg | 3 |
Gunzenhausen | 2 |
Henryk | 2 |
Moscow | 2 |
San Francisco | 2 |
Toronto | 2 |
Washington | 2 |
Abingdon | 1 |
Baltimore | 1 |
Brooklyn | 1 |
Grùmolo | 1 |
Indiana | 1 |
Motala | 1 |
Paris | 1 |
Philadelphia | 1 |
Scottsdale | 1 |
Seremban | 1 |